
Pfizer board member stepping down
pharmafile | May 21, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Marc Tessier-Lavigne, Pfizer
Dr Marc Tessier-Lavigne is leaving Pfizer’s board of directors to work on the launch of Denali, a new biotech company focussed on neurodegenerative disease therapies.
Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company.
“We’d like to thank Dr Tessier-Lavigne for his service on Pfizer’s board, particularly for his expertise and counsel in scientific matters,” says Ian Read, Pfizer chairman and chief executive.
“While we regret the loss of Marc’s service, we congratulate him on the launch of Denali and offer him our best wishes for all of his future endeavours,” adds Read.
“I want to thank Pfizer for the opportunity to serve on its board of directors,” notes Tessier-Lavigne. “Pfizer is an outstanding company, and I wish it continued success.”
Tessier-Lavigne was appointed to Pfizer’s board of directors in December 2011, and most recently served as a member of the Regulatory and Compliance Committee and Science and Technology Committee.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






